Study S002072

A 26-Week,Randomised,Open-Label,Multicenter,Active-Controlled,Parallel-Design,Phase III Clinical Trial to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide Injection With XULTOPHY® Once Daily Via Subcutaneous Injection in Chinese Subjects With Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration: NCT06559722
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: UNKNOWN
Enrollment: 510
Start: 2024-08
Primary completion: 2025-10
Lead sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd
Conditions: Type 2 Diabetes
Interventions: DRUG:Insulin Degludec/liraglutide Injection; DRUG:XULTOPHY®
Results posted: FALSE

Registered primary outcomes

Change from baseline in HbA1c after 26 weeks of treatment [Baseline, Week 26]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.